The pharma sector is experiencing robust growth. The Nifty Pharma index rose by 33.61 percent in 2023, and it has gained nearly 5 percent from January till May 29. Similarly, the BSE Healthcare index increased by 36.97 percent in 2023.
In light of the pharma sector's growth, Sharekhan, a stock brokerage firm, has recommended four pharma funds to investors. These mutual funds cater to those interested in investing in pharma sector companies, with all four funds allocating 80 percent of their funds exclusively to pharma stocks. Additionally, they invest in stocks of hospitals and medical companies, providing approximately 50 percent returns within a year.
The recommended pharma funds are:
Aditya Birla Sun Life Pharma & Healthcare Fund
Nippon India Pharma Fund
Tata India Pharma And Healthcare Fund
ICICI Prudential Pharma Healthcare and Diagnostics Fund
As of January 25, the NAV of the first fund is Rs 26.7, with a total fund value of Rs 585 crore. It has yielded returns of 50.14 percent in the last year, and SIP has provided investors with a return of 33.2 percent.
The NAV of the second fund is Rs 448, with a fund value of Rs 6470 crore. It has returned 48.59 percent in the last year, and SIP investors received returns of 31.13 percent.
The NAV of the third fund is Rs 27, with a fund value of Rs 760 crore. It has given returns of 46.05 percent in the last year, and SIP has provided investors with a return of 30.66 percent.
The NAV of the fourth fund is Rs 30.4, with a fund value of Rs 3360 crore. It has yielded a return of 51.98 percent in one year, and SIP has given investors a return of 33.47 percent.
Data in this section is not a buy/sell recommendation but only a compilation of information on various technical/volume-based parameters
Analyst certifies that all of the views, if any, expressed in this report reflect his personal views about the subject company or companies and its or their securities, and no part of his compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Analyst affirms that there exists no conflict of interest that can bias his views in this report. The Analyst does not hold any share(s) in the company/ies discussed.
General Disclaimer and Terms & Conditions of the research report
INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. For a detailed disclaimer and disclosure please visit https://www.vikatan.com/business/share-market/113898-disclaimer-disclosures. Before making an investment/trading decision on the basis of this data you need to consider, with the assistance of a qualified adviser, whether the investment/trading is appropriate in light of your particular investment/trading needs, objectives and financial circumstances.
One year Price history of the daily closing price of the securities covered in this section is available at https://www.nseindia.com/report-detail/eq_security (Choose the respective symbol) /name of company/time duration)
Before investing, an investment decision should be taken in consultation with a SEBI registered investment advisor. It can be profitable to wait for the right opportunities and buy fewer when those opportunities are available.